


CLAIMS

What is claimed is:

1. A compound of Formula II:



(Formula II)

and/or a pharmaceutically acceptable salt thereof.

2. A pharmaceutically acceptable salt of claim 1.
3. A composition comprising the compound or pharmaceutically acceptable salt of claim 4 or 5 and a pharmaceutically acceptable carrier.
4. A composition comprising about 70% or more of the compound or pharmaceutically acceptable salt of claim 1.
5. The composition of claim 4,
wherein the composition comprises about 90% or more of a compound or pharmaceutically acceptable salt of claim 1.
6. A composition of any preceding claim wherein the composition is or comprises a bead, tablet, capsule, solution, or suspension.
7. An *in vitro* method of inhibiting the proliferation of a cell, the method comprising contacting said cell with an antiproliferative amount of a compound, pharmaceutically acceptable salt, or composition of any preceding claim.

8. A compound, pharmaceutically acceptable salt, or composition of any preceding claim for inhibiting the proliferation of a cell.

9. The method of claim 7 or compound of claim 8, wherein the cell is a human cell, optionally wherein the cell is a human cancer cell.

10. The method or compound of claim 9, wherein the human cell is a human cancer cell selected from the group consisting of a blood cancer, bone cancer, solid tumor, adenocarcinoma, brain cancer, glioblastoma, breast adenocarcinoma, bone marrow cancer, erythroleukemia, osteosarcoma, colorectal carcinoma, epidermoid carcinoma, epithelial carcinoma, uterine carcinoma, fibrosarcoma, gastric adenocarcinoma, kidney cancer, leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, leiomyoblastoma, lung carcinoma, small cell lung carcinoma, lymphoma, B cell lymphoma, Burkitt's lymphoma, T cell lymphoma, melanoma, malignant melanoma, neuroblastoma, leukemia ovarian cancer, ovary adenocarcinoma, pancreatic cancer, prostate adenocarcinoma, rhabdomyosarcoma, renal cell carcinoma, sarcoma, uterine sarcoma, squamous cell carcinoma, bladder squamous cell carcinoma, head and neck cancer, and transitional cell carcinoma.

11. A compound, pharmaceutical salt, or composition of any preceding claim for use in treating a mammal having a disease, optionally wherein the mammal is human.

12. The compound for the use of claim 11, wherein the disease is cancer and the cancer is selected from the group consisting of a blood cancer, bone cancer, solid tumor, adenocarcinoma, brain cancer, glioblastoma, breast adenocarcinoma, bone marrow cancer, erythroleukemia, osteosarcoma, colorectal carcinoma, epidermoid carcinoma, epithelial carcinoma, uterine carcinoma, fibrosarcoma, gastric adenocarcinoma, kidney cancer, leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, leiomyoblastoma, lung carcinoma, small cell lung carcinoma, lymphoma, B cell lymphoma, Burkitt's lymphoma, T cell lymphoma, melanoma, malignant melanoma, neuroblastoma, leukemia ovarian cancer, ovary adenocarcinoma, pancreatic cancer, prostate adenocarcinoma, rhabdomyosarcoma, renal cell carcinoma, sarcoma, uterine sarcoma, squamous cell carcinoma, bladder squamous cell carcinoma, head and neck cancer, and transitional cell carcinoma.


13. The compound for the use of claim 11 or 12, wherein the compound of Formula I and/or Formula II is to be administered as the sole active pharmaceutical agent(s); or the compound(s) of Formula I and/or Formula II is to be administered in combination with one or

more of a chemotherapeutic agent, anti-cancer agent, or immune modulator; and/or radiation therapy and/or surgery.

14. The compound for the use of claim 13, wherein the mammal is in need of prevention of organ transplant rejection or host-versus-graft disease.

15. The compound for the use of any one of claims 11 - 14, wherein the administration is to be via a route selected from the group consisting of parenteral, oral, topical, buccal, sublingual, transdermal, a medical device, a stent, inhalation, injection, subcutaneous, intramuscular, or intravenous; wherein the administration comprises a single dose or multiple doses at the same or different dosages; and/or the members of a combination are administered physically and/or temporally simultaneously or separately, optionally wherein the compound of Formula I and/or Formula II is provided as a bead, tablet, capsule, solution, or suspension.

16. A process for preparing a compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, the process comprising a feeding starter of Formula III



(Formula III)

where X = H, alkyl, sodium or potassium, to a rapamycin-producing strain that has been genetically altered to remove or inactivate the rapK gene or a homologue thereof.